ImmunoGen Message Board - Msg: 34079729

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gary Mohilner who wrote (5648)	11/14/2022 4:57:37 PM
From: Area51	of 5665

IMGN: ImmunoGen announces FDA accelerated approval of ELAHERE businesswire.com ImmunoGen Inc. shares rose 8.9% to $6.27 in after-hours trading Monday after the company said the Food and Drug Administration granted accelerated approval for elahere. The antibody-drug conjugates for cancer treatments company said elahere's approval is for treatment of adults with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next